The Cancer Genome Atlas (TCGA) network study of 12 cancer types (PanCancer 12) revealed frequent mutation of TP53, and amplification and expression of related TP63 isoform ΔNp63 in squamous cancers. Further, aberrant expression of inflammatory genes and TP53/p63/p73 targets were detected in the PanCancer 12 project, reminiscent of gene programs comodulated by cREL/ΔNp63/TAp73 transcription factors we uncovered in head and neck squamous cell carcinomas (HNSCCs). However, how inflammatory gene signatures and cREL/p63/p73 targets are comodulated genome wide is unclear. Here, we examined how the inflammatory factor tumor necrosis factor-α (TNF-α) broadly modulates redistribution of cREL with ΔNp63α/TAp73 complexes and signatures genome wide in the HNSCC model UM-SCC46 using chromatin immunoprecipitation sequencing (ChIP-seq). TNF-α enhanced genome-wide co-occupancy of cREL with ΔNp63α on TP53/p63 sites, while unexpectedly promoting redistribution of TAp73 from TP53 to activator protein-1 (AP-1) sites. cREL, ΔNp63α and TAp73 binding and oligomerization on NF-κB-, TP53-or AP-1-specific sequences were independently validated by ChIP-qPCR (quantitative PCR), oligonucleotide-binding assays and analytical ultracentrifugation. Function of the binding activity was confirmed using TP53-, AP-1-and NF-κB-specific REs or p21, SERPINE1 and IL-6 promoter luciferase reporter activities. Concurrently, TNF-α regulated a broad gene network with cobinding activities for cREL, ΔNp63α and TAp73 observed upon array profiling and reverse transcription-PCR. Overlapping target gene signatures were observed in squamous cancer subsets and in inflamed skin of transgenic mice overexpressing ΔNp63α. Furthermore, multiple target genes identified in this study were linked to TP63 and TP73 activity and increased gene expression in large squamous cancer samples from PanCancer 12 TCGA by CircleMap. PARADIGM inferred pathway analysis revealed the network connection of TP63 and NF-κB complexes through an AP-1 hub, further supporting our findings. Thus, inflammatory cytokine TNF-α mediates genome-wide redistribution of the cREL/p63/p73, and AP-1 interactome, to diminish TAp73 tumor suppressor function and reciprocally activate NF-κB and AP-1 gene programs implicated in malignancy.
INTRODUCTION
The Cancer Genome Atlas (TCGA) project aims to provide a comprehensive catalog of the key genomic changes in major cancer types, to foster effective diagnosis, treatment and prevention. The recently published TCGA HNSCC (head and neck squamous cell carcinoma) project, including 279 patient tissues, revealed that 484% of human papillomavirus-negative HNSCC harbor genetic alterations in tumor suppressor TP53, concurrent with amplification and expression of related family member ΔNp63 in~47% cases, and altered TNF-α-NF-κB/REL, inflammation and death pathways in~60% of cases. 1 In addition, the TCGA network PanCancer 12 project performed integrative analyses on 3527 specimens of 12 cancer types, using five genome-wide highthroughput platforms. 2 The project revealed a unique convergence that classified squamous cell carcinoma (SCC) of head and neck, lung and a subset of bladder cancers into a common 1 Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA; subtype called 'squamous-like'. 2 This genomic classification suggests that those squamous cancer types shared more molecular similarities than other tumor types from the same tissue of origin. Consistent with findings in the HNSCC TCGA project, the hallmarks of these squamous cancers include high rates of TP53 mutation, amplification and overexpression of oncogenic isoform ΔNp63, and altered activation of TP53/TP63/ TP73 and immune pathway genes linked to NF-κB/REL transcription factors. These newly identified SCC signatures raised several critical questions, including how and to what extent do TP63/TP73 and NF-κB/REL family transcription factors interact to regulate global gene programs in squamous cancers?
The TP53 family comprises TP53, TP63 and TP73 and their isoforms. TP53 is the most frequently mutated tumor suppressor gene in cancer, especially in squamous cancers, and is described as the 'guardian of the genome'. Mutation or inactivation of TP53 promotes genomic instability by disrupting cell cycle arrest, DNA repair, senescence, apoptosis and autophagy of irreversibly damaged cells. 3 Interestingly, however, the other TP53 family members, TP63 and TP73, are infrequently mutated, and can potentially compensate for disrupted TP53, 4, 5 but their shared and distinct functions appear to be more complex than those of TP53 in tumorigenesis, as suggested by TCGA findings. TP63 and TP73 isoforms share a core structural architecture, sequence homology and potential but usually weaker tumor suppressor function than TP53, whereas they also exhibit distinct roles in development, adhesion, tumor promotion and inflammatory responses in normal and malignant epithelia. 4, [6] [7] [8] The TA isoforms contain full-length N-terminal-transactivating domains that function as TP53 homologs, whereas ΔN isoforms having a truncated N terminus can serve as antagonists of TP53 and its TA counterparts, as well as promote cancer gene programs. 9, 10 However, the genome-wide role and mechanisms whereby ΔNp63α/TAp73 promote tumorigenesis and linked to inflammation in cancer are undefined.
We recently revealed that inflammatory cytokine TNF-α stimulates binding of NF-κB subunit cREL with ΔNp63 to form a protein complex and displacement of TAp73 DNA binding, leading to the repression of growth arrest and apoptotic genes p21, NOXA and PUMA. 6 Complexes between cREL, RELA and ΔNp63 were also implicated in reciprocal activation of several NF-κB-regulated genes. 8 Interestingly, the NF-κB family proto-oncogene cREL is amplified and overexpressed in a subset of HNSCC and other cancers, 11 but its functions are less well characterized. 12 These experimental data suggest the hypothesis that NF-κB and TP53 family members could coordinate wider global and reciprocal cross-talk between cell death, survival and inflammatory gene programs. Specifically, are these interactions between cREL, ΔNp63α and TAp73 part of a novel mechanism that reciprocally regulates a genome-wide oncogenic program? Do the reciprocal interactions between cREL and ΔNp63α with TAp73 indicate their capability to bind TP53, NF-κB or other DNA response elements (REs)? Finally, what is the fate and functional significance of TAp73 displaced by the cREL/ΔNp63α complexes?
To answer these questions, we performed genome-wide chromatin immunoprecipitation assay, followed by highthroughput sequencing (ChIP-seq), and microarray profiling in HNSCC cell lines to explore the genome-wide regulatory role of cREL/ΔNp63α and TAp73 complexes. Furthermore, bioinformatic analysis of in vivo data from TCGA, immunohistochemistry and tissue array of HNSCC, and a ΔNp63α transgenic mouse model supports their contribution in the regulation of the cancer gene program. These findings present a new paradigm for how TNF-α and these TFs orchestrate gene programs implicated in cancerrelated inflammation, survival and migration, and help explain the mechanisms underpinning the dysregulated network of TP53/TP63 and inflammation observed in the Pan-TCGA project. enrichment and colocalized binding of cREL,  TP63α and TAp73 in the regulatory regions and around  transcription start sites genome wide  To investigate cREL, p63α and TAp73 binding activity genome  wide, ChIP-seq was performed using UM-SCC46 cells, previously  shown to exhibit higher expression of mtTP53, TP63 and TP73 proteins, and TNF-α modulation of their interactions in target gene regulation representative of HNSCC with mtTP53. 6 We confirmed that TNF-α induced cREL and ΔNp63α, and partially decreased multiple TAp73 isoforms in nuclear extracts (Figure 1a) , where TAp73 is predominantly detected in UM-SCC46 and other HNSCC lines under baseline conditions (Supplementary Figure S1A) . TNF-α increased total genomic binding peak numbers and peak associated genes by cREL and p63α, while partially decreasing TAp73 binding activity (Figure 1b and Supplementary Table S1) , and similar patterns were seen on individual chromosomes (Supplementary Figures S1B and S2 ). We observed that the percentage of genome-wide bindings were disproportionately enriched near or within genes (promoter, intragenic, transcriptional termination site region) compared with much larger intergenic regions (Figure 1c , upper panels). Cumulatively, over half of the binding peaks were within the promoter (~7-12%) and intragenic regions (35-41%). These perigenic region peak distributions were significantly enriched compared with the whole-genome background distribution, tested using the exact binomial test (Supplementary Figure S3) . The binding activities within the intragenic regions were enriched in the first intron ( Figure 1c , lower panels). After TNF-α treatment, cREL and p63α binding were substantially induced near the transcriptional start sites (TSSs), whereas the basal TAp73 TSS binding peak did not appreciably change in the presence of TNF-α (Figure 1d ). The intersection sets of three TF binding peaks within 1 kb distance were identified, showing that intersecting binding peaks under basal conditions (215) were significantly increased after TNF-α treatment (1159) (Figure 1e , upper and lower left; Fisher's exact test, P = 2.2e − 16). The 793 TAp73 basal binding peaks intersected with TNF-induced cREL and p63α binding (Figure 1e , lower right). After combination of all binding activities, 1217 candidate binding peaks were observed, which aligned within the regulatory loci of genes and generated 530 genes displayed cobinding by the three TFs (Supplementary Figure S4) . Furthermore, the physical distance between the intersections of three TF binding peaks was examined, defined as within 1 kb distance on the same chromosome ( Figure 1f ). TNF-α increased intersection binding peaks between cREL and p63α, or between p63α and TAp73, around the TSS within o200 bp (Figure 1f , upper two panels), when compared with other intersections (Figure 1f , lower panels). More detailed results were included in the Supplementary Information. Taken together, these data show that TNF-α modulated the colocalization of cREL, p63α and TAp73 binding enriched around TSSs.
RESULTS

TNF-α promotes
De novo motif search defines genome-wide binding on TP53 and AP-1 consensus elements modulated by TNF-α Next, the top motifs most frequently bound by the three TFs under different treatment conditions were identified using Gibb's motif sampler and summarized ( Binding of purified cREL homology domain and TP73 DNA-binding domain to cREL, TP53 and AP-1 REs Next, we purified recombinant cREL Rel homology domain and TP73 DNA-binding domain (DBD) proteins and tested their ability to bind oligonucleotides with minimal consensus sequences from cREL, TP53 and AP-1 REs (Figure 2f ). Analytical ultracentrifugation with fluorescein-labeled DNA allowed us to measure sedimentation velocities of the protein-DNA complexes and classify their oligomerization state. Remarkably, cREL exhibited binding activities for all three REs, with a higher affinity for its own RE (Figure 2f , left). TP73 DBD exhibited dimeric DNA-protein complexes for all three REs tested; however, the tetramer complex was only observed for the TP53 RE (Figure 2f, right) . Thus, our binding experiments with purified proteins confirmed that both cREL Rel homology domain and p73 DBD are able to bind not only to their own consensus sequences but also to the other DNA REs, supporting the binding to motifs identified in the ChIP-seq experiment.
Validation of colocalized binding on individual gene promoters by ChIP-qPCR and oligo-based binding assays Representative peak binding activities of four of the genes detected by ChIP-seq are presented in Supplementary Figure S6 . We further validated the specific binding activities of the three TFs on regulatory regions of eight representative genes detected by ChIP-seq and confirmed the binding by ChIP-PCR (Figures 3a-c  and Supplementary Table S2 ). Treatment with TNF-α significantly increased cREL and/or p63α binding (Figures 3a and b) , whereas TAp73 binding was partially decreased or not significantly changed ( Figure 3c ). Next, we performed a different binding experiment using short~50-70 bp synthetic oligonucleotides containing 10-20bp sequences of individual or a combination of predicted consensus motifs (Figure 3d and Supplementary Table S3 ). We observed a relatively stronger basal TAp73 binding activity when compared with p63α binding, consistent with the ChIP-seq and ChIP-qPCR results. Interestingly, the oligonucleotide containing a predicted AP-1 motif (p21-c) without the other motifs also exhibited TAp73 binding. These binding activities detected by ChIP-seq were validated by two different experimental methods. Thus, our current study provided evidence for the colocalization of cREL, ΔNp63 and TAp73 to multiple target promoters and REs in response to TNF-α, consistent with our previous publications. 6, 8 cREL, ΔNp63α and TAp73 modulate transcriptional regulation and gene expression Next, we performed functional validation using luciferase reporters containing p53-, AP-1-and NF-κB/REL-specific consensus REs after coexpression of ΔNp63α, TAp73, cREL or empty control vectors ( Figure 4a ). Overexpressed TAp73 was a strong inducer of classical TP53 RE reporter activity, which was downmodulated by TNF-α ( Figure 4a , upper left). Both ΔNp63α and TAp73 also induced significant AP-1 RE-inducing activity, and TNF-α further enhanced it (upper middle). cREL induced strong NF-κB reporter activity that was increased by TNF-α, whereas ΔNp63α and TAp73 exhibited less pronounced effects (upper right). Then, the individual promoters of p21-containing TP53, p63 REs, SERPINE1 with AP-1 RE and IL-6 with AP-1 and NF-κB REs were tested for their activities (Figure 4a , lower panels). TAp73 was the strongest inducer of p21 and SERPINE1. ΔNp63α was the strongest inducer of IL-6, whereas mutation of either the NF-κB or the AP-1 RE significantly suppressed the activity. Taken together, these data further confirm the overlapping capability of these TFs to modulate p53, AP-1 and NF-κB/REL transcriptional activities.
We examined how TNF-α and three TFs modulated the expression of six candidate genes identified through ChIP-seq and confirmed by microarray ( Figure 5 below and Supplementary Figure S6 ). ΔNp63α and TAp73 strongly induced GADD45A, a known TP53 target, 13 as well as AP-1 subunit FOSL1 and SERPINE1 ( Figure 4b , upper panels). CEBPA was strongly repressed by ΔNp63α and TAp73 (Figure 4b , lower left panel). The modulation of MAP4K4 and CFLAR (FLIP) by the three TFs was distinct, in that cREL plus TNF-α, ΔNp63α alone and ΔNp63α plus TNF-α significantly induced gene expression. Collectively, TNF-α-modulated cREL, ΔNp63α and TAp73 can differentially regulate a functionally diverse gene repertoire.
TNF-α globally modulates the expression of genes with colocalized binding of TFs Next, we tested if TNF-α globally modulates the expression of genes exhibiting colocalized binding of cREL, p63α and TAp73 ( Figure 5 ). A total of 1050 genes with ⩾ 1.5-fold differential expression were identified during at least one time point after TNF-α treatment. Without TNF-α, a quarter of altered genes exhibited TF binding, while TNF-α significantly increased upand downregulated genes bound by the TFs by~10%, together Table S2 ). In the genes of interest, the overlapping binding peaks were located in promoter/enhancer regions (SERPINE1, BCL3, CEBPA, HBEGF) or in first (CDKN1A, FOSL1, TNFSF10) or other (GADD45A) introns. qPCR was performed in independent ChIP experiments, and isotype antibody served as the negative control. (a-c) ChIP binding activity of cREL (a), p63α (b) and TAp73 (c). Blue, untreated; red, TNF-α treated. The data are presented as the mean ± s.d. from three replicates. (d) The DNA sequences were extracted from ChIP-seq peaks and the core p53, p63, AP-1, NF-κB and cREL consensus motifs were predicted and depicted. Nuclear extracts were isolated from UM-SCC46 cells and the binding assays were performed using a 96-well colorimetric binding assay with 50-70mer oligos containing the 10-20bp motifs synthesized and labeled with biotin (Supplementary Table S3 ). Open bars, anti-p63α antibody; dashed bars, anti-TAp73 antibody. Neg, negative control using p21 control oligo without lysate. p21-P, positive control using a p21 oligo containing the known TP53/TP63 site. The data are presented as the mean ± s.d. calculated from three replicates. Figure 4 . cREL, ΔNp63α and TAp73 modulate transcriptional regulation and differential gene expression. (a) UM-SCC46 cells were transfected with luciferase reporter plasmids containing specific TP53, AP-1 or NF-κB REs (upper panels), or the promoter sequences of p21 (TP53, TP63 REs), SERPINE1 (AP-1 REs) or IL-6 (AP-1 and NF-κB REs; lower panels). Overexpression of cREL, ΔNp63α or TAp73α was induced by TNF-α treatment (20 ng/ml) for 48 h. IL-6 binding site-specific point mutant promoter constructs included the deletion mutation of NF-κB or AP-1 binding sites without TNF-α (bottom right panel). The relative reporter activity was normalized to the corresponding β-gal activity and/or compared with the control vectors. Blue, untreated; red, TNF-α treated, except in IL-6 reporter assay (bottom right panel). In IL-6 reporter assay without TNF-α treatment, blue: reporter with full-length IL-6 promoter; red: IL-6 promoter with the NF-κB binding motif deleted; green: IL-6 promoter with the AP-1 binding motif deleted. (b) The newly identified target genes were validated by qRT-PCR 48 h after cREL, ΔNp63α or TAp73α overexpression under TNF-α treatment (20 ng/ml). The data are presented as the mean ± s.d. of three replicates from one representative experiment. Blue, untreated; red, TNF-α treated. Statistical significance was calculated using a two-tailed Student's T-test, Po0.05. *Statistical significance when comparing the conditions with overexpressed plasmids versus control plasmid.
# Statistical significance when comparing untreated versus TNF-α-treated condition. , upregulated genes, P = 4.3E − 07; downregulated genes, P = 5.5E − 05). The number of differentially expressed genes with individual or overlapping binding activities for the three TFs are presented for basal activities (Figure 5c ), or for TNF-α-modulated activities (Figure 5d ). From these, we identified those genes displaying cobinding of all three transcription factors that were up-or downregulated by TNF-α from Figures 5c and d, and Figure 6 . cREL, ΔNp63 and TAp73 nuclear and cytoplasmic localization and target gene expression in human HNSCC tissues and skin of ΔNp63α transgenic mice. (a) Forty-six upregulated and 27 downregulated genes from Figure 5d were queried using the mRNA expression data set from TCGA HNSCC project, which includes 279 tumor and 16 mucosa specimens. Significant upregulation of 13/46 activated genes (red) and downregulation of 10/27 repressed genes (blue) are detected in TCGA tumors compared with normal samples (fold change ⩾ 1.5, Student's t-test with false discovery rate (FDR) o1% multivariate comparison correction cut off ). (b) Three publicly available data sets of gene profiling microarrays were investigated, which included a total of 125 (67 metastatic and 58 non-metastatic) HNSCC tissues. Pearson's correlation coefficients of gene expression between p63 and potential target genes were calculated, and genes exhibiting statistically significant correlation are presented. The line indicates P o0.05. (c) RNA was isolated from the skins of ΔNp63α transgenic mice (red). qRT-PCR was performed to quantify gene expression levels with a statistically significant increase compared with their age-matched nontransgenic littermates (blue, P o0.05). The data were calculated from triplicates of one representative experiment and presented as the mean ± s.d. (d) Human HNSCC and normal mucosa frozen sections were stained for cREL, ΔNp63 and TAp73, and intensities within nuclei or cytoplasm in three × 200 fields per slide were acquired and quantified using an Aperio Scanscope and Cell Quantification Software (Vista, CA, USA), and presented as mean histoscores ± s.d. for 8-13 samples. *Po 0.05, HNSCC vs normal mucosa by t-tests. (e) Immunohistochemistry comparing transcription factors JUNB and FOSL1 nuclear staining in human HNSCC tissue array. Images were acquired using an Aperio Scanscope at × 200 magnification, and staining intensity was quantified using Aperio Cell Quantification Software. Tumor protein expression of evaluable specimens for JUNB and FOSL1 (n = 66) and mucosa (n = 11) samples. Student's t-test, Po 0.05. (f) Associations in expression levels between the transcription factors nuclear cREL with targets nuclear JUNB and IKKε (stage III tumors), nuclear cREL with nuclear FOSL1 (in all tumor stages), and nuclear TP63 with nuclear SERPINE1/PAI1 (metastatic tumors). A non-directional test for the significance of the Pearson's product-moment correlation coefficient with the computed histoscores for each protein was used.
redundant genes. Altogether, TNF-α upregulated 46 genes and downregulated 27 genes with overlapping binding of cREL, p63α and TAp73, which were selected for hierarchical gene clustering and displayed in heatmaps (Figure 5e TNF-α regulates ΔNp63α/TAp73 and NF-κB interactome H Si et al cREL, ΔNp63 and TAp73 expression and altered gene and protein signatures in HNSCC tissues and ΔNp63α transgenic mouse skin We examined the 46 TNFα-upregulated genes and 27 downregulated genes cobound by all three TFs from Figure 5e using the HNSCC mRNAseq expression data set recently published for 279 primary tumor and 16 mucosa specimens from TCGA.
1 Using these data, we found that 23/73 genes (31.5%), including 13 of 46 activated genes and 10 of 27 repressed genes, showed significant concordance when comparing primary HNSCC tumor with mucosa specimens (Figure 6a ; fold change ⩾ 1.5, P o0.05, Student's t-test with false discovery rate correction o 1% cutoff). An additional 23 genes (31.5%) were also expressed in the same direction as in cell lines, but below the significance threshold (Supplementary Table S6 ). Thus, overall 63% of genes showed consistent changes in direction of expression when comparing primary tumors with mucosa between cell line data and TCGA human tissue data. Consistent with this, an unsupervised cluster analysis and heatmap of the TCGA data for all 73 genes confirms that many of the TNFα-inducible and downregulated genes in cell lines cocluster among four major tumor subsets (Supplementary Figure S8, clusters a-d) . Among the TNF-α-inducible genes, several of the most significantly upregulated genes cocluster predominantly in major clusters (a and/or b) (SERPINE1, MET, SPOCK1, CRISPLD2, TINAGL1, LEPREL1, TNS3, PARP14, CDH3), which have previously been reported in PubMed to be deregulated in cancer and/or metastasis. MET and SERPINE1 are implicated in cell migration, invasion and metastasis, and SERPINE1 is also a downstream target of MET signaling. [14] [15] [16] [17] As additional TP63-bound and -modulated genes identified in our data set are implicated in cancer, inflammation and metastasis, we also examined 48 TP63 targets, including 31 curated from the literature, and 17 from our prior 8 or present study of TNF-α-modulated genes (Supplementary Figure S7) , as described in Supplementary Methods. An expression-based method was used to cluster a group of genes with common profiling patterns and TP63 transcription factor motifs, to computationally infer coexpressed networks, using three independent publicly available microarray data sets containing 125 HNSCC samples that include 58 non-metastatic and 67 metastatic HNSCC tissues. [18] [19] [20] Among these genes, a statistically significant correlation was established between the expression of TP63 and 35 genes (71.4%, Pearson's correlation coefficient Po 0.05; Figure 6b ). This analysis provided evidence for differential expression of multiple TP63-linked genes that are implicated in cancer cell phenotype (e.g. JUNB/FOSL1, CDKN1A, JAG2/ NOTCH2), invasion and metastasis (e.g., SERPINE1, MET, SNAI2, MMP10) and inflammation (e.g. IL-1A, IL-8, RELB). Several of these TP63 target genes also comodulated by TNF-α cocluster together in major subsets of TCGA HNSCC tumors (Supplementary Figure S8; e.g., FOSL1, CDKN1A, SERPINE1, MET, TNFAIP8).
We further compared ΔNp63-bound and -upregulated genes in a conditional K5-ΔNp63α transgenic mouse model, where increased TNF-α expression and a similar nuclear redistribution of cREL/ΔNp63 and TAp73 was observed. 21, 22 Array profiling detected increased expression of a panel of upregulated genes, including AP-1 subunits Fosl1 and Junb, and NF-κB pathwayrelated genes, Traf1, Ikkε and Relb (Figure 6c ).
We next validated if proteins of TNF-α-comodulated TFs and four target genes identified in multiple platforms above display corresponding alterations in human HNSCC tumor and tissue arrays. The nuclear-cytoplasmic distribution of cREL, ΔNp63 and TAp73 in human specimens was quantified by immunohistochemistry score. We observed increased cREL and ΔNp63, and decreased TAp73 nuclear distribution, with a reciprocal decrease in cytoplasmic cREL and increased TAp73 cytoplasmic staining in HNSCC (Figure 6d and Supplementary Figure S9) , consistent with TNF-α-modulated nuclear redistribution and DNA binding of these TFs in HNSCC in vitro (see Figures 1a and b) and prior studies. 6, 8 Next, we examined the protein expression of target genes in human HNSCC tissue array, which contains 61 primary tumors of stages I-IV at different anatomic locations, 8 lymph node metastatic tumors and 11 normal mucosa tissues (Supplementary Methods). Notably, key AP-1 family transcription factor targets, JUNB and FOSL1, showed significantly elevated nuclear staining in HNSCC tumors relative to mucosa (Figure 6e) , consistent with altered AP-1 promoter binding and expression of JUN1B and FOSL1 observed above (Figures 3-5) . Further, the nuclear staining of JUNB and FOSL1 was significantly correlated when compared with cREL ( Figure 6f ). Increase in staining for two additional targets, IKKε and SERPINE1, were also significantly correlated with cREL and p63 staining, respectively. Taken together, these data from human and mouse tissues support our hypothesis for the altered cellular distribution and functional comodulation of cREL, ΔNp63α, TAp73, with AP-1 subunits JUNB/ FOSL1, and a subset of other target genes detected in different in vitro and in vivo systems.
CircleMap and Pearson's correlation analyses support TP53/p63/p73-modulated gene signatures in squamous cancers We next examined how our current findings may relate to large data sets and analyses from the recently published TCGA PanCancer 12 project, which identified inflammatory as well as a 'TP53-like' compensatory gene expression activity pattern associated with increased ΔNp63 and TP73 activities, and frequent genomic inactivation of TP53 in the squamous-like tumors. 2 These squamous cancers included 293 HNSCCs, 156 lung SCCs and 24 bladder SCCs, which were analyzed for TP53/63/73 status and expression and function of eight genes identified among their known and new targets in the present study. Figure 7a shows predominantly occupies TP53 or p63 binding sites, whereas NF-κB family member cREL either resides in the cytoplasm or in the nucleus with binding on AP-1 sites, and ΔNp63α is found in the nucleus unbound to DNA (upper left). TNF-α, a major inflammatory cytokine produced in the tumor microenvironment, can promote cREL nuclear translocation, and complexes with ΔNp63α, to occupy TP53/p63 binding sites. TNF-α also induces nuclear displacement or reprogramming of TAp73 to bind neighboring AP-1 sites (right panels). These dynamic alterations diminish TAp73 tumor suppressor activity, while enhancing cREL/ΔNp63α-and TAp73-mediated inflammatory and cancer gene programs. This model helps explain how TNF-α modulates NF-κB and AP-1 signaling while altering tumor suppressor activity, to promote gene programs implicated in inflammation, survival and metastasis (lower left panels).
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CircleMaps, which enable a multidimensional comparison of the genomic alterations, expression and inferred pathway activities for TP53, ΔNp63, TP73 and these target genes, using the annotated PARADIGM bioinformatics analytic platform. 23, 24 The TP53 CircleMap shows that the majority of SCC tissues contain TP53 mutations (second circle), and/or copy number loss (third circle) with corresponding decrease in TP53 expression (fourth circle). However, they retain weak inferred PARADIGM activity for TP53 (the outer circle), which cannot be explained by inactivated TP53, but could be compensated by overlapping function of other family members. Consistent with this, the TP63 CircleMap exhibited high copy number gain, expression and PARADIGM gene signatures, supporting a role for copy number gain and expression in TP63 PARADIGM gene activity. Similarly, TP73 overexpression and PARADIGM activity are also congruent. We further analyzed eight targets identified in this study, including genes involved in cell cycle (CDKN1A, GADD45), signal receptor and kinase (MET, MAP4K4), transcription factors (AP-1/FOSL1, CEBPA) and secreted factors (SERPINE1, IL-6). The expression and PARADIGM activity of ΔNp63, TP73 and these target genes are higher across SCC tumors compared with other cancer types. By Pearson's correlation analysis (Figure 7b ), ΔNp63 exhibited significant positive correlation with four genes bound and inducible by TNF-α, including MAP4K4, FOSL1 and GADD45, whose activation ΔNp63 and TNF-α promotes, and a negative correlation with CEBPA, repressed by ΔNp63 and TNF-α (Figures 4b and 5e ). TP73 exhibited a negative association with IL-6, which TAp73 suppresses, and a positive correlation with CDKN1A (p21), which it activates (Figure 4a) . SERPINE1 showed only a weak negative association with TP73, which was observed with TNF-α treatment by reporter but not by RT-PCR (Figures 4a and b) .
PARADIGM SuperPathway analyses connect p63, NF-κB and AP-1 subnetworks in squamous cancers Our current and prior experimental data indicate that ΔNp63 and REL NF-κB family members bind and modulate inflammation and survival genes (Figures 3-5) . 6, 8, 25 Analyses of TCGA PanCancer 12 data sets also revealed a strong TP63 gene signature associated with altered immune and inflammatory gene signatures in squamous cancers. 2 However, the network(s) linking TP63 and NF-κB family members and target genes has not been well elucidated. We thus searched within the interconnected network of differentially activated PARADIGM pathways, linked through regulatory hubs with 415 downstream targets, derived from a larger interconnected network displaying differentially activated proteins inferred between the C2-squamous-like subtype and other tumors, as detailed in Supplementary Methods, Supplementary Table S5 and Supplementary Figure S10 . 26 Interestingly, we observed increased activation of the network neighborhood surrounding TP63, connected with NF-κB complex (RELA/p50) through AP-1 (JUN/FOS) complexes within the squamous cancers (Figure 7c ). The activation of these networks and targets are consistent with our evidence that TNF-α orchestrates cREL/ΔNp63 binding and induction of AP-1 subunits, reprograming of cREL/p73 binding via AP-1 binding consensus sites and their related gene signatures in vitro and in vivo (Figures 2-6 ). Several genes shown on the network identified in this study have been independently validated previously, such as TP63-regulated CDKN1A, GADD45A, IL-1A, CHUK, YAP1, IGFBP3 and KRT14, as well as NF-κB-and AP-1-related genes IL-6, IL-8, and MAPK1/ERK/JUN/FOS pathways. Most of these related genes in squamous cancers are activated (red) when compared with other cancer types. Furthermore, a more extended network connecting ΔNp63α, TP53 and AP-1 transcription complexes (among other regulatory hubs) links a larger number of target genes identified in this study by existing experimental data (Supplementary Figure S10A) . Although not all target genes identified from our current study are linked by this expanded network (Supplementary Figure S10A-B) , they are significantly enriched among the 4213 differentially activated PARADIGM proteins inferred between squamous and other cancers (hypergeometric test P = 6E − 9 for basal targets, and P = 1.22E − 10 for TNF-α-responsive targets, Supplementary Table S5) .
DISCUSSION
Here, we provide evidence for a novel and dynamic genome-wide TF binding paradigm, whereby the inflammatory cytokine TNF-α modulated binding activities of cREL, ΔNp63α and TAp73 genome wide, intersecting a diverse repertoire of genes implicated in the malignant phenotype. This modulation was linked to attenuated expression of specific TP53 tumor suppressor targets and promotion of REL/NF-κB and AP-1 oncogenic and inflammatory gene programs (Figure 8) . Our study provides a link between global TP63/TP73-, AP-1-and NF-κB-mediated survival and inflammatory gene programs, which helps explain the finding of unique TP63/TP73 gene signatures compensating for mutant TP53 identified recently in squamous cancers from TCGA HNSCC and PanCancer projects.
1,2 Furthermore, our current data are consistent with previous mechanistic studies demonstrating how TNF-α-induced changes alter the DNA binding of cREL, ΔNp63 and TAp73 family members. 6, 8 Our studies showed that these transcription factors regulate genes involved in several aspects of cell fate including cell proliferation, stemness, survival/ apoptosis and migration, as well as epithelial cell growth, inflammation and immune responses in murine keratinocyte and ΔNp63 transgenic mouse models. 27, 28 After cross-comparison of 12 different cancer types, TCGA PanCancer 12 project uncovered several unique signatures that differentiate squamous cancers from other cancer types, such as high rates of TP53 mutation and TP63 amplification. 2 In-depth genetic analyses of the gene signatures of squamous cancers revealed attenuated TP53 and increased expression of compensatory TP63/TP73 gene signatures. These were not strictly linked with the relatively infrequent loss of heterozygosity or TP53-truncating loss-of-function mutations, but with TP63 amplification and TP63/73 gene expression by PARADIGM-Shift analysis. 23 Interestingly, our previous experimental results supported a relationship between attenuated TP53 target gene expression and partial compensatory function of TP53 family members TP63 and/ or TP73 in SCC. 6, 8 HNSCC with mtTP53 displayed higher ΔNp63 and TAp73, and intermediate 'compensatory' basal expression of several TP53/TP63/TP73-regulated apoptotic genes. Expression of these genes was further attenuated by TNF-α, DNA binding interaction of cREL with ΔNp63 and displacement of TAp73. 6 In the present study, ChIP-seq, ChIP PCR and binding analyses provide evidence for genome-wide reprogramming of TAp73 binding to AP-1 RE-containing promoters, and varying regulation of target genes of TP53 as well as AP-1 and REL/NF-κB. Such TP63/ TP73 compensatory TP53 function has been associated with higher sensitivity to cisplatin chemotherapy in both HNSCC 29, 30 and in BRCA1-related triple-negative breast cancer, 31 but together with promotion of opposing inflammatory and oncogenic gene programs, is apparently insufficient to prevent development of these cancers.
TP53 is highly mutated in HNSCC,~80-90% in human papillomavirus-negative tumors, as evident by recent TCGA data. 1 As we previously reported in the manuscript by Lu et al., 6 the increased expression of TAp73 is predominantly observed in mtTP53 cell lines, and reduced TAp73 occupancy is associated with replacement by cREL, but not mtTP53, in response to TNF-α. The mtTP53 does not co-immunoprecipitate with the cREL/ΔNp63 complex, and is not recruited to p21, NOXA or PUMA promoters by ChIP assay following TNF-α treatment. In addition, dependence on cREL and ΔNp63 for TAp73 binding to p21 promoter was shown, whereby cREL inversely modulated TAp73 binding. Similar results for TNF-α treatment or cREL modulation of TAp73 were obtained in three UM-SCC lines. 6 Furthermore, our prior data are also consistent with other's evidence for a strong protein interaction is between p63 and p73, but not with TP53, because TP53 is lacking the SAM domain at the C terminal, which mediates heterotetramerization between these family members. 32, 33 Our prior and current findings help further clarify the apparent function of TP63/TP73 in compensating for TP53 and promoting oncogene expression. First, such compensatory activity is associated with enhanced expression of typical TP53 target genes, such as CDNK1A/p21 and GADDA45, which control cell cycle, 9, 30 observed in our cell line model (Figures 3-5) , broader microarray studies of HNSCC tissues (Figure 6b ) and PanCancer 12 TCGA project ( Figure 7) . However, TNF-α, cREL and ΔNp63 modulate TAp73, attenuating its TP53 compensatory function, while also enhancing a much broader oncogene program implicated in cancer promotion. 6, 8 This includes growth factor-mediated signaling, inflammatory cytokines, prosurvival transcription factors such as AP-1 and RELs and antiapoptotic genes (e.g. CFLAR) (Figures 4-6) , which can potentially counter and limit compensatory TP53 tumor suppressor function. Second, as shown by our and other laboratories, as well as in PanCancer 12 project, ΔNp63α is the dominant isoform expressed in squamous cancers. 2 We and others have shown the strong oncogenic activity of ΔNp63α in squamous cancers, including promoting tumor cell proliferation, migration, colony formation and inflammatory responses. 8 Third, as our and other laboratories previously showed and supported by HNSCC and PanCancer 12 TCGA project, a subset of squamous cancers exhibited inflammatory signatures concurrent with TP63/TP73 compensatory activity.
2 Such inflammatory signaling mediated by TNF-α could reprogram TP73 tumor suppressor to oncogenic activity by binding to AP-1 sites, as supported by ChIP-seq, ChIP RT-PCR and binding assays (Figures 1-4 ) in this study. This novel finding is also supported by the PanCancer 12 data, indicating that inflammatory gene signatures linked by cytokine TNF-α and NF-κB transcription factors are connected to TP63 gene signatures through JUN/FOS-mediated pathway and network (Figure 7c and Supplementary Figure S10) .
The novel finding from this study of physical interaction among these TFs with genomic DNA is supported, among other evidence, by a narrow binding peak within~200 bp surrounding TP53/p63 consensus sites, and a broader peak of~400-500 bp within which nearby AP-1 motifs are distributed. Interestingly, a~500 bp distance between p73 binding and AP-1 sites was independently identified in ChIP-seq experiments in osteosarcoma cells, where anti-TAp73α and c-Jun antibodies detected cobinding by ChIP-re-ChIP assay. 34 In addition, Pietenpol and co-workers 35 identified overlapping AP-1 and p73 binding sites in ChIP-seq experiments, and confirmed c-Jun binding within 500 bp of p73 binding sites in rhabdomyosarcoma cells. Furthermore, we identified palindromic binding sequences for TP53/p63 and AP-1 (Figure 2 ), which are similar to the sequences of TP53/TP63/TP73 and nearby AP-1 binding motifs observed in previous studies. [34] [35] [36] [37] [38] [39] Our study reveals that in the absence of TNF-α, TAp73 was mainly bound to TP53/TP63 consensus motifs, consistent with that found for growth arrest and proapoptotic genes in multiple HNSCC lines including UM-SCC46, 6 where TAp73 exhibited a partial compensatory function for mutated TP53. 9 However, previous studies have not observed how TNF-α induced dynamic alterations of these TF binding activities. After TNF-α treatment, ΔNp63α bound at TP53/ TP63 sites previously occupied by TAp73, while TAp73 bound to AP-1 sites (Figures 2c and d) . These dynamic alterations of binding activities reversed TAp73 tumor suppressor activity, while increased cREL/ΔNp63α and TAp73 modulated the expression of inflammatory-and cancer-related gene programs.
Our previous study demonstrated that TNF-α modulates reciprocal and mutually exclusive protein-protein interactions between endogenous nuclear ΔNp63α/TAp73 and cREL/ΔNp63α complexes. 6, 8 Our prior ChIP studies did not resolve if cREL or TAp73 can individually bind the same minimal TP53 RE, or if TP73 can bind to AP-1 REs independent of ΔNp63α or other cofactors. Our sedimentation velocity centrifugation experiments revealed that both cREL and TP73 bind these DNA REs and can form dimers and/or tetramers upon DNA binding. These results provide biophysical support to the model of colocalized binding of cREL and TP73 suggested by the ChIP-seq and bioinformatic analyses. Collectively, the different experimental approaches provide mechanistic details of how TFs can occupy binding sites at the same as well as very close promoter sequences.
Our reporter assays provide evidence for functional overlap in transcriptional activities in addition to binding, which demonstrate differing effects of the TFs and TNF-α on modulation of transcription (Figure 4a ). The reporters contained TP53, AP-1 or NF-κB REs. ΔNp63α exhibited minimal effects on TP53, decreased p21 and significantly induced IL-6 expression. This induction was significantly reduced by mutation of the NF-κB and AP-1 REs, which is consistent with our and others' publications. 8, 40 Significantly, TAp73α strongly induced p21 and SERPINE1 reporter activity, consistent with its compensatory function for mutant TP53, 9, 31, 35, 41, 42 as well as induced specific AP-1 promoter activity. 43, 44 In addition, reporters with specific TP53 or AP-1 REs demonstrated the ability of TNF-α to repress TAp73-induced TP53 RE, or enhance TAp73-mediated AP-1 RE transactivation, supporting a reciprocal role for TNF-α in modulating these REs.
TNF-α, an inflammatory cytokine produced in the tumor microenvironment of many cancers, was previously shown to activate both NF-κB and AP-1, 45 ,46 the latter through MEK/ERK signaling. These findings are also consistent with the Pan-TCGA data, where the squamous-like cancer type exhibited elevated activity of MAPK signaling pathways. 2 Here, we propose an expanded model, wherein TNF-α-modulated TAp73 also appears capable of reprogrammed binding of AP-1-containing REs, while inducing coexpression of AP-1 family member FOSL1/Fra1 and reporters containing AP-1 REs. In addition, FOSL1 and JunB expression were significantly associated with p63 and p73 expression in human HNSCC cells and ΔNp63α transgenic mice. This is consistent with our finding that FOSL/Fra1, c-Jun and JunB are the major AP-1 protein family members expressed and bound to AP-1 sites, and which mediate cell proliferation and migration in HNSCC cell lines. 47, 48 Our data are supported by others' observations that p73 and AP-1 family members can enhance each other's binding and transcription activities. 35, 43, 44 Our present study adds new evidence that TNF-α is a key factor that induces binding of TAp73 to AP-1 sites and increases AP-1 family member transcription, and suggests a new model whereby TNF-α can comodulate AP-1 and reprogram TAp73 to cooperatively activate AP-1 target genes.
Thus, our and others' studies help explain why when TP53 is mutated or defective in function, the TAp73 compensatory function for TP53 is repressed. First, overexpressed ΔNp63α is able to form a complex with TAp73 to block its tumor suppressor function. 6, 8, 31 Second, TNF-α promotes displacement of TAp73 from proapoptotic genes and reprograms its binding and activation of AP-1 sites (Figures 2a, 2d, 2e and 3c) . Third, nuclear TAp73 binding is displaced from TP53/p63 sites by the cREL/ ΔNp63α complex as supported by experimental validations (Figures 2 and 3) . 6 Instead, TAp73 function is converted to potentiate AP-1 activity and promote survival and inflammatory gene expression ( Figure 5 ), as supported by other studies. 34, 43 Furthermore, in an independent study of a group of genes predicted to be controlled by c-Jun/NF-κB, 49 20% of genes overlapped with the genes differentially regulated by TAp73. 34 Taken together, our current and recent studies 6, 8, 48 reveal a complex, genome-wide transcriptional regulatory mechanism whereby TP53, NF-κB and AP-1 family members interact to promote TNF-α regulates ΔNp63α/TAp73 and NF-κB interactome H Si et al a broad signaling network favoring tumor survival and inflammation. Our current study helps explain the global mechanisms underlying the newly discovered deregulated TP53/p63 network and inflammation, presented recently by TCGA PanCancer project, 2 and a study in neuroblastoma. 50 The transcriptional regulatory mechanisms mediated by TP53, NF-κB and AP-1 family members genome wide are far more complex and nuanced than originally anticipated, and understanding the mechanisms will shed light on more effective means for targeting of cancer therapeutics.
MATERIALS AND METHODS
ChIP and next-generation sequencing (ChIP-seq) DNA fragments bound by antibodies were prepared following the ChIP protocol using sheared DNA (~100-400 bp). The DNA samples were sequenced using a next-generation GAIIx sequencer from Illumina (San Diego, CA, USA) following the manufacturer's protocol. Sequence reads were mapped to the UCSC human genome Hg18 assembly using the Eland algorithm (Illumina), permitting up to two mismatches and no gaps. Only unique mapped reads were used in the binding peak calling analysis. To identify binding peaks, we used MACS, 51 in which a dynamic Poisson distribution model was used to detect the statistically significant binding peaks in ChIP samples compared with DNA input controls. MACS is a widely used algorithm for detection of protein-DNA binding sites when analyzing ChIP-seq data. This method is specifically designed to detect the promoter transcription factor binding sites, which are typically located within a few hundred DNA base pairs. In our study, the default setting was selected, which is commonly used and suitable to our data sets. Detected peak regions were visualized mainly by using the CisGenome browser 52 together with gene structure, DNA sequences and conservation scores. We compared the fraction of peaks residing in various genomic features with the corresponding genome background using the CEAS program. 53 A binomial test was used in this method to obtain the P-value of each comparison. Gibbs Sampler 54 was used for the de novo motif search for binding site sequences and MEME-ChIP suit 55 was used to process the found motifs and compare the results to known motifs in database. Peak location, distance to TSSs, peak intersection, motif location and intersection analysis were performed using customized python/R scripts. ChIP-seq experiments were repeated in UM-SCC46 cell lines, and a representative experiment was analyzed and presented in Supplementary Table S1 . Minimal background peaks were observed in the samples of input DNA or DNA from isotype control antibodies. This study used the highperformance computational capabilities of the Biowulf Linux cluster at the National Institutes (Health, Bethesda, MD, USA; http://biowulf.nih.gov).
